-
-
-
-
-
-
-
Zymeworks authorizes $125 million share repurchase program
-
-
-
-
-
-
-
Zymeworks secures $250 million in royalty-backed financing from Royalty Pharma
-
-
-
-
-
-
-
Zymeworks (ZYME) PT Raised to $40 at Leerink Partners
-
-
-
-
-
-
-
Zymeworks Reports Fourth Quarter and Full Year 2023 Financial Results
-
-
-
-
-
-
-
Zymeworks Announces Appointment of Derek J. Miller to its Board of Directors
-
-
-
-
-
-
-
ALL BLUE CAPITAL EXPANDS ITS LEADERSHIP TEAM TO SUPPORT PROPOSED ACQUISITION OF ZYMEWORKS INC.
-
-
-
-
-
-
-
Exelixis In-Licenses Iconic Therapeutics’ Tissue Factor-Targeting Antibody-Drug Conjugate Ahead of Planned Investigational New Drug Application
-
1,170,803 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

